key: cord-0744065-fn6y0b6s
authors: Codina, Helena; Vieitez, Irene; Gutierrez-Valencia, Alicia; Skouridou, Vasso; Martínez, Cristina; Patiño, Lucía; Botero-Gallego, Mariluz; Trujillo-Rodríguez, María; Serna-Gallego, Ana; Muñoz-Muela, Esperanza; Bobillo, María M.; Pérez, Alexandre; Cabrera-Alvar, Jorge Julio; Crespo, Manuel; O’Sullivan, Ciara K.; Ruiz-Mateos, Ezequiel; Poveda, Eva
title: Elevated anti-SARS-CoV-2 antibodies and IL-6, IL-8, MIP-1β, early predictors of severe COVID-19
date: 2021-04-13
journal: bioRxiv
DOI: 10.1101/2021.04.13.439586
sha: a86447cf0ecd40d9571754a63df800ddfd64f368
doc_id: 744065
cord_uid: fn6y0b6s

Background Viral and host immune kinetics during acute COVID-19 and after remission of acute symptoms need better characterization. Methods SARS-CoV-2 RNA, anti-SARS-CoV-2 IgA, IgM, and IgG antibodies, and pro-inflammatory cytokines were measured in sequential samples among hospitalized COVID-19 patients during acute infection and 6 months following diagnosis. Results 24 laboratory-confirmed COVID-19 patients with mild/moderate and severe COVID-19 were included. Most were males 83%, median age of 61 years. 21% were admitted to the ICU and 8 of them (33.3%) met criteria for severe COVID-19 disease. A delay in SARS-CoV-2 levels decline during the first 6 days of follow-up and viral load persistence until month 3 were related with severe COVID-19, but not viral load levels at the diagnosis. Higher levels of anti-SARS-CoV-2 IgA, IgM, IgG and the cytokines IL-6, IL-8 and MIP-1β at the diagnosis time were related with severe COVID-19 outcome. Higher levels of MIP-1β, IL-1β, MIP-1α and IFN-γ were observed at month 1/3 during mild/moderate disease compared to severe COVID-19. IgG persisted at low levels after 6 months of diagnosis. Conclusions Higher concentrations of IgA, IgM, and IgG, and IL-6, IL-8 and MIP-1β are identified as early predictors of COVID-19 severity, but not SARS-CoV-2 RNA levels at diagnosis.

Coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), rapidly spread worldwide becoming a global public health emergency. COVID-19 can be asymptomatic or mild in most cases, but it can rapidly progress to a severe lung inflammation leading to Acute Respiratory Distress Syndrome (ARDS), especially for older adults (> 80 years) and/or with comorbidities (i.e., serious heart conditions, chronic pulmonary disease, diabetes mellitus, or hypertension among others) [1] [2] [3] . The disease outcome mainly depends on the characteristics of the viral replication and host immune responses, which can end up resolving the infection efficiently or creating an exacerbated inflammation associated with severe lung damage pathology, organ failure and poor outcomes [4, 5] .

The comprehensive long-term kinetics of SARS-CoV-2 RNA levels, anti-SARS-CoV-2 antibodies (i.e., IgA, IgM, and IgG) and specific pro-inflammatory cytokines during and after COVID-19 is not fully characterized, and it is of great interest for the identification of early predictive biomarkers of severe disease and to understand the clinical outcomes of patients after the remission of acute symptoms.

This study comprises an evaluation of clinical, virological and immunological responses in a well-characterized cohort of hospitalized COVID-19 patients with mild/moderate and severe disease. We performed a close follow-up at different time points from the time of diagnosis and up to 6 months after the confirmation of the SARS-CoV-2 infection. Moreover, we were able to identify viral and host-immune biomarkers associated with COVID-19 severity. A delay in the SARS-CoV-2-RNA clearance in the upper respiratory tract during the first days of the disease, higher concentrations of anti-SARS-CoV-2 IgA, IgM, and IgG, and of specific cytokines (i.e., IL-6, IL-8 and MIP-1β) at baseline were associated with COVID-19 severity. Overall, after 6 months, anti-SARS-CoV-2 IgG persisted although at low levels.

The study population was selected from the COVID-19 Cohort of the Galicia Sur Health Research Institute (COHVID-GS) (https://www.iisgaliciasur.es/apoyo -a-lainvestigacion/cohorte-covid19/). This cohort includes laboratory-confirmed SARS-CoV-2 patients in clinical follow-up at the Vigo Healthcare Area with epidemiological/clinical data and with a repository of biological samples (i.e., nasopharyngeal swabs, serum, plasma and peripheral blood mononuclear cells-PBMCs) stored at the Galicia Sur Health

Research Institute Biobank. The epidemiological/clinical information was collected in a Case Report Form (CRF) specifically predesigned for the COHVID-GS. The cohort also includes a control group of uninfected individuals (anti-IgA, IgM and IgG SARS-CoV-2 negative). Written informed consent was obtained from each individual enrolled in the COHVID-GS. All the techniques were performed in BLS-2 conditions, according to the biosafety guidelines for handling and processing specimens associated with COVID-19 (https://www.cdc.gov/coronavirus/2019-ncov/lab/lab-biosafety-guidelines.html).

The selection criteria for this study were SARS-CoV-2 adult hospitalized patients with a very close clinical follow-up with nasopharyngeal swabs, serum and plasma samples, with consecutive samples available at least at baseline; and day 3 or 6; and month 1 or 3 from their inclusion in the COHVID-GS. Moreover, only those patients included in the COHVID-GS between day 1 and 5 following the confirmation of the SARS-CoV-2 infection by RT-qPCR were considered. Serial paired nasopharyngeal swabs, serum and plasma samples were collected from each patient at baseline, day 3 or 6, month 1 or 3 and at month 6. We also included 30 serum samples from healthy and non-infected individuals as controls for the immunoassay experiments. Epidemiological and clinical data were recorded for the study population.

Following WHO guidance, severe COVID-19 was defined as the need for invasive mechanical ventilation, the development of Acute Respiratory Distress Syndrome (PO2/FiO2 < 300 mmHg or Saturation O2/FiO2 < 330) or the admission to an Intensive Care Unit (ICU) [6] . Patients who did not meet severe criteria were considered as mild/moderate COVID-19.

Viral RNA was extracted from 140 µL of nasopharyngeal swab samples using the QIAmp viral RNA mini kit (QIAGEN, Hilden, Germany) and the automatized QIAcube system (QIAGEN, Hilden, Germany), and was eluted in 50 µL of buffer following the manufacturer's instructions. The positive (SARS-CoV-2 Standard, EDx Exact Diagnostics) and negative (SARS-CoV-2 Negative, EDx Exact Diagnostics) controls were also extracted using the same procedure.

SARS-CoV-2 viral load was quantified by reverse transcriptase droplet digital PCR (RT-ddPCR), including the one-step reverse transcription (One-Step RT-ddPCR Advanced Kit for Probes, Bio-Rad Laboratories) and the triplex probe assay for PCR amplification (2019-nCoV CDC ddPCR Triplex Probe Assay, Bio-Rad Laboratories). The assay contains primers and probes targeting two regions of the SARS-CoV-2 nucleocapsid gene (N1 and N2) and the human RNase P gene (RPP30). The reaction mixture was performed with 5.5 µL of SARS-CoV-2 RNA sample and following the manufacturer's instructions. All the samples were tested in duplicate. Data analysis was performed using the QuantaSoft Analysis Pro Software (Bio-Rad Laboratories) which showed the results as copies per microliter of 1x ddPCR reaction. All viral load values were recalculated to copies per millilitre of swab, and the sensitivity threshold was 100 copies/mL. To assess the accuracy of the absolute viral RNA quantification, two-fold serial dilutions of the positive control were analysed for lineal regression analysis. Finally, to establish a reliable comparison between the viral load of different samples, the absolute quantification of SARS-CoV-2 RNA was normalized with RPP30 and expressed as copies/10 4 cells (supplementary material section). 

A total of 24 hospitalized laboratory-confirmed COVID-19 patients were included in the study. The demographic and most relevant clinical characteristics related with COVID-19 are shown in Table 1 . Most 83% (20/24) were males with a median age of 61 years old (IQR: 48-75.3). Nearly 50% (12/24) of patients met obese criteria (BMI ≥ 30) and 42% (10/24) had hypertension. The median hospitalization time was 8 days, and 21% (5/24) were admitted to the ICU. Eight of them (33.3%) met criteria for severe COVID-19 disease.

The SARS-CoV-2 viral load quantification was performed from 92 RNA samples extracted from nasopharyngeal swabs in the 24 patients at different time-points (24 at baseline, 18 at day 3, 13 at day 6, 5 at day 15, 16 at month 1, and 16 at month 3) ( Table   2) outcomes. A delay for the significant decline of SARS-CoV-2 levels during the first 6 days of follow-up was recognized for those patients with severe disease. Thus, while for patients with mild/moderate disease a significant decline in viral load is observed since the diagnosis time, for patients with severe disease is only observed after day 6 ( Figure   1B ).

The anti-SARS-CoV-2 antibodies levels were quantified at different time-points from a total of 109 serum samples (24 at baseline, 18 at day 3, 13 at day 6, 5 at day 15, 16 at month 1, 18 at month 3 and 15 at month 6) (Figure 2) . Overall, a high variability in the IgA baseline levels was observed among patients that progressively increase reaching the highest median levels at day 6 of follow-up, and then, significantly decrease until month 6 (p= 0.028). The highest levels of IgA at baseline and during the follow-up were observed for patients with severe COVID-19 (COV 006, COV 008, COV 010, COV 014, COV 013) (Figure 2A) . A similar pattern was observed for the kinetics of IgM with an on-going increase reaching the maximum levels at day 6 with a significant decline after that (p=0.028). Likewise to IgA, the highest levels of IgM at baseline and during the follow-up were observed for patients with severe COVID-19 (COV 008, COV 011, COV 010, COV 020) ( Figure 2B ). For IgG there was also a gradual increase until day 6 with a progressive but slowly decrease until month 6 reaching very low concentrations ( Figure 2C ). Of note, IgG levels at month 6 were significantly higher than for a group of 30 uninfected controls (15.93 vs. 4.50 μg/mL, respectively p-value < 0.001) ( Figure 2D ).

The numerical data for IgA, IgM and IgG in serum during the study period are shown as supplementary data (Supplementary Table 1 ).

Plasma cytokines levels were performed in a total of 18 patients, 12 with mild/moderate and 6 with severe COVID-19, at different time-points (18 at baseline, 15 at month 1, 14 at month 3, and 17 at month 6). Table 3) .

In this study we report that elevated levels of anti-SARS-CoV-2 antibodies, IgA, IgM, and IgG as well as specific cytokines such as IL- Overall, SARS-CoV-2 viral load kinetics follows the pattern described previously, reaching maximum levels during acute infection and decreasing progressively until becoming undetectable in most patients in less than one month following diagnosis [7] [8] [9] [10] . However, because of the close follow-up of these patients we were able to identify a significant delay during the first days of viral load decay for patients who met the criteria for severe COVID-19. Nonetheless, in our cohort, SARS-CoV-2 RNA levels were not associated with the clinical outcome at any time point. There are some controversial data regarding this issue, while some studies have not reported any association between SARS-CoV-2 viral load during acute infection and COVID-19 severity [11, 12] others point out that elevated viral load could be used to identify patients at higher risk for morbidity or severe COVID-19 outcome [13, 14] . The controversial results might be explained for the heterogeneity of the studies related to the different characteristics of the study population and/or the methodology used for SARS-CoV-2 quantification and sampling quality (i.e., normalization using copies/cells).

Although, 80% of patients showed undetectable viremia one month after the diagnosis, in 5 patients we observed SARS-CoV-2 RNA persistence between month 1 and 3. Interestingly, all of these had severe disease and/or comorbidities (i.e., diabetes, hypertension or cardiovascular disorders, chronic lung disease and HIV infection, dyslipidemia). These observations are in agreement with previous studies that reported an association between SARS-CoV-2 RNA persistence with severe disease [9, 15] and comorbidity [13, [16] [17] [18] following remission of the acute symptoms. More recently, Jacobs et al., highlighted the association between SARS-CoV-2 plasma viremia with ICU admission [19] and Tokuyama et al., described SARS-CoV-2 persistence in intestinal enterocytes up to 7 months after symptoms resolutions [20] . Additional studies are required to better understand the clinical significance of SARS-CoV-2 persistence in different compartments (i.e., plasma, gut, upper respiratory tract) and its potential use to monitor COVID-19 patients during the early acute infection and/or following the remission of the acute symptoms.

We found that elevated levels of anti-SARS-CoV-2 antibodies during acute infection are related with severe COVID-19. Those patients who developed ARDS showed significantly higher levels of IgA, IgM, and IgG, compared to patients without ARDS. These findings are in agreement with previous studies that found an association between anti-SARS-CoV-2 antibodies levels and the need for intubation or death [21, 22] . Overall, we observed that anti-SARS-CoV-2 IgA and IgM antibodies decay rapidly after the acute infection phase (i.e., at month 3, 54% for IgA and 77% for IgM showed levels below the limit of detection) but the decline for IgG was less prominent and persisted until month 6. These levels were still significantly higher compared to the levels of uninfected controls (15.93 vs. 4 .50 μg/mL, respectively p-value < 0.001). The durability of the immune responses against SARS-CoV-2 infection is a matter of intense interest and still remains unclear. Regarding the humoral responses, recent studies have also reported that IgG levels persist between 6 and 8 months after onset of symptoms [23, 24] . However, plasma neutralization activity seems to decrease a few weeks after the onset of the symptoms [25] . Understanding the dynamics of antibodies against SARS-CoV-2 and the persistence of the neutralizing activity is critical to establish correct prevention and vaccination strategies.

COVID-19 severity has been associated with an exacerbated inflammation due to a massive release of pro-inflammatory components [4, 5] . We have identified that [26, 27] and play a pivotal role in the cytokine storm in response to SARS-CoV-2 infection promoting organ failure and severe lung pathology [28] [29] [30] . IL-8 leads the activation and the recruitment of neutrophils to the inflammation sites and has been implicated in inflammatory pulmonary diseases such as ARDS, chronic obstructive pulmonary disease, and asthma [31, 32] . MIP-1β drives the recruitment of a variety of innate and adaptive immune cells and high concentrations have been reported in the serum and lungs of patients with certain acute respiratory viral infections [33, 34] . However, their role during SARS-CoV-2 infection remains unclear.

Some studies have reported a higher production of MIP-1β at the transcriptional level in bronchoalveolar lavage cells isolated from the lungs of severe COVID-19 patients [35, 36] , whilst other studies did not find an association between MIP-1β and severe disease [28, 37] .

The levels of IL-6, IL-8, and MIP-1β significantly decline at month 1 showing similar levels during the follow-up to those patients with mild/moderate disease. Overall, a similar dynamic was observed for IP-10, TNF-and sCD25 during the study period.

By contrast, the dynamic for MIP-1β, IL-1β, MIP-1 and IFN-showed a different evolution pattern with a significant increase at month 1 and/or 3 among patients with mild/moderate disease compared to those with severe COVID-19. No differences were observed in the levels of these cytokines 6 months after of the acute SARS-COV-2 infection between patients with mild/moderate vs. severe disease. Therefore, the unbalance in the cytokine levels between severe and mild/moderate COVID-19 patients seems to be restored after 6 months of SARS-CoV-2 infection. A previous study by Lucas et al., [38] also reported no differences at the IL-6, IL-8 and IP-10 levels between mild/moderate and severe outcomes after 20 days of follow-up.

This study presents some limitations. First, the relatively small size of the study population mainly represented by men as during the first wave of COVID-19 in our institution 86% of hospitalized patients were men. However, we were able to accomplish a very close follow-up of the clinical outcomes, viral and host immune factors in this population allowing interesting observations. Although we have identified IgG after 6 months of SARS-CoV-2 infection we did not assess their neutralization activity and therefore the risk upon new SARS-CoV-2 re-infections. External validation should be assessed to confirm the predictive value of our findings.

In conclusion, in a well-characterized cohort of hospitalized COVID-19 with mild/moderate and severe disease and close clinical follow-up during and after 6 months of SARS-CoV-2 infection we have recognized early host immune predictors of severity.

Higher levels of IgA, IgM, and IgG and the specific cytokines IL-6, IL-8, and MIP-1β during acute infection were observed in those patients with a severe COVID-19 outcome.

Conversely, higher levels of IL-1β and IFN-and at month 1 and MIP-1β, IL-1β, MIP-1 and IFN-month 3 were observed among patients with mild/moderate diseases compared to those with severe COVID-19. IgG against SARS-CoV-2 persisted after 6 months of the diagnosis.

We would like to thank all the members of COHVID-GS and IISGS Biobank, patients, nursing staff and Celta Ingenieros (A Coruña, Spain) for their kind supply of ddPCR reagents. supported by the Instituto de Salud Carlos III, cofinanced by the European Development Regional Fund ("A way to achieve Europe"), Subprogram PFIS (FI19/00304). C.K was supported by Fondo COVID19 of Instituto de Salud Carlos III (COV20/00823).

The authors declare no competing interests. ARDS* 30% (7) Myalgia/Arthralgia 30% (7) Anosmia 25% (6) Chest pain 25% (6) Median Oxygen therapy 58% (14) Invasive mechanical ventilation 21% (5) Pulmonary infiltrates 92% (22) Treatments during hospitalization Hydroxychloroquine 71% (17) Antibiotics 46% (11) Immunosuppressive therapy 46% (11) Corticosteroids 42% (10)

Lopinavir/Ritonavir 42% (10) Azithromycin 30% (7) Data are median (IQR), % (n). *Acute Respiratory Distress Syndrome. ** n=23 

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

The Clinical Characteristics and Risk Factors of Severe COVID-19

Dysregulation of Immune Response in Patients With Coronavirus

The pathogenesis and treatment of the `Cytokine Storm' in COVID-19

World Health Organization. COVID-19 Clinical management: living guidance. World Health Organization 2021

SARS-CoV-2 detection, viral load and infectivity over the course of an infection

Temporal dynamics in viral shedding and transmissibility of COVID-19

Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort

Detection and quantification of SARS-CoV-2 by droplet digital PCR in real-time PCR negative nasopharyngeal swabs from suspected COVID-19 patients

Association of Initial Viral Load in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patients with Outcome and Symptoms

SARS-CoV-2 viral load in nasopharyngeal swabs in the emergency department does not predict COVID-19 severity and mortality

High SARS-CoV-2 load in the nasopharynx of patients with a mild form of COVID-19 is associated with clinical deterioration regardless of the hydroxychloroquine administration

Association Between Upper Respiratory Tract Viral Load, Comorbidities, Disease Severity, and Outcome of Patients With SARS-CoV-2 Infection

Clinical and virological data of the first cases of COVID-19 in Europe: a case series

Diabetes mellitus is a risk factor for prolonged SARS-CoV-2 viral shedding in lower respiratory tract samples of critically ill patients

Risk factors for viral RNA shedding in COVID-19 patients

Dyslipidemia Increases the Risk of Severe COVID-19: A Systematic Review, Meta-analysis, and Meta-regression

COVID-19 outcome: insights from quantification of viremia and neutralizing antibody

SARS-COV-2 persists in intestinal enterocytes up to 7 months after symptom resolution

COVID-19-neutralizing antibodies predict disease severity and survival

Antibody responses to SARS-CoV-2 in patients with COVID-19

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Evolution of antibody immunity to SARS-CoV-2

Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals

Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2

An inflammatory cytokine signature predicts COVID-19 severity and survival

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical and immunological features of severe and moderate coronavirus disease 2019

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients

Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases

Expression and function of chemokines during viral infections: from molecular mechanisms to in vivo function

Chemokine regulation of inflammation during respiratory syncytial virus infection

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19

Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19

Serum Cytokine and Chemokine Profile in Relation to the Severity of Coronavirus Disease 2019 in China

Longitudinal analyses reveal immunological misfiring in severe COVID-19

IL-6 IL-8 IP-10 TNF-sCD25 MIP-1β IL-1β MIP-1 IFN